Journal of International Obstetrics and Gynecology ›› 2017, Vol. 44 ›› Issue (2): 185-188.

Previous Articles     Next Articles

Gene Therapy Advances of CRISPR/Cas9 in β-thalassaemia

LI Huan-rong,LI Zeng-yan   

  1. Department of Gynecology and Obstetrics,Tianjin Medical University General Hospital,Tianjin 300052,China
  • Received:2016-12-27 Revised:2017-01-19 Published:2017-04-15 Online:2017-05-18
  • Contact: LI Zeng-yan,li_zengyan@sina.com E-mail:414967423@qq.com

Abstract: 【Abstract】  β-thalassaemia is a genetic disease of human β-globin (HBB) gene mutation, there is no cure possible, leading to the disorder of globin expression. CRISPR/Cas system, as the acquired immune system of bacteria and archaea, can transform the genome of many organisms at present. CRISPR/Cas9 systems is widely used for the advantages of easy programming, inexpensive construction, high specificity and multiplexed genome editing. The latest study using CRISPR/Cas9 systems combined with induced pluripotent stem cells to correct human HBB has become possible,meanwhile produces normal hemoglobin to reduce the symptom of patients with β-thalassaemia. The outcome will be a tremendous disasters, if off-target effect occured in human, that′s scientist worried about. To increase the safety of CRISPR/Cas9 gene editing, the latest research avoid the off-targets effect by increasing the specificity of CRISPR resection and controlling the Cas9 effectively. We reviewed the latest researches on the CRISPR/Cas9 systems and deal with off target effects.
【Keywords】 

Key words: beta-thalassemia, Genes, Therapy, CRISPR/Cas